Xadago launched; eyes now on pipeline assets
Following an encouraging year to date we have upgraded our forecasts for Xadago (Parkinson’s disease [PD] therapy), and key CNS pipeline assets sarizotan (Rett syndrome) and Evenamide (schizophrenia). Sublicensee partner US WorldMeds launched Xadago into the US market in July 2017; Xadago is now available in the majority of key markets worldwide through partners. Importantly Newron’s CNS R&D pipeline is progressing; clinical data and commercial opportunity details presented on Evenamide and sarizotan at the R&D day in May have prompted upgrades to our peak sales forecasts and valuation. Our updated valuation is CHF754m.
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
- Xadago launched; eyes now on pipeline assets13 Oct 2017